{"id":202182,"date":"2026-08-13T16:06:32","date_gmt":"2026-08-13T10:36:32","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=202182"},"modified":"2026-08-13T16:06:34","modified_gmt":"2026-08-13T10:36:34","slug":"nifty-pharma-today-13-august-2026-16-00","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/nifty-pharma-today-13-august-2026-16-00\/","title":{"rendered":"Nifty Pharma Today: Index Performance, Stocks & Analysis"},"content":{"rendered":"

Nifty Pharma<\/a> today closed on a mildly weak note, reflecting a session where losers outnumbered gainers even though a few stocks posted strong upside moves. The index stood at 26,686.8, down 75.7 points or 0.28% versus the previous close of 26,762.5. That makes the day important for anyone tracking sector performance today, because the headline fall was relatively small, but the internal breadth was softer than the index move alone suggests.<\/p>\n

For traders and investors following Nifty Pharma live, the session showed a classic split market within the healthcare and pharma pack. A handful of names such as Natco Pharma, Gland Pharma and Ajanta Pharma advanced strongly, but broader weakness in stocks including JB Chemicals & Pharmaceuticals, Zydus Lifesciences, Abbott India and several heavyweight names kept the sector under pressure. This is why reading only the index level can be misleading; the stock-by-stock movement offers a much clearer picture.<\/p>\n

At an index level, Nifty Pharma opened at 26,710.65, touched an intraday high of 26,712.35, and slipped to a low of 26,537.45 before settling at 26,686.8. The fact that the index traded close to its opening level on the upside but moved noticeably lower on the downside indicates that sellers had greater intraday control. In simple terms, buying interest was present in select counters, but it was not broad enough to overpower declines across the rest of the basket.<\/p>\n

This detailed Nifty Pharma performance update covers the latest index snapshot, market breadth, complete constituent performance, top gainers, top losers, heavyweight stock behavior, a practical price-action read, and the key levels investors should monitor next. The analysis is based on available verified price and breadth data for 13 August 2026.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n